- Home
- SSBK vs ACIU Comparison
SSBK vs ACIU Comparison
Compare SSBK & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSBK
- ACIU
- Stock Information
- Founded
- SSBK 2007
- ACIU 2003
- Country
- SSBK United States
- ACIU Switzerland
- Employees
- SSBK N/A
- ACIU N/A
- Industry
- SSBK Commercial Banks
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- SSBK Finance
- ACIU Health Care
- Exchange
- SSBK Nasdaq
- ACIU Nasdaq
- Market Cap
- SSBK 330.0M
- ACIU 294.9M
- IPO Year
- SSBK 2021
- ACIU 2016
- Fundamental
- Price
- SSBK $34.63
- ACIU $2.65
- Analyst Decision
- SSBK Buy
- ACIU Strong Buy
- Analyst Count
- SSBK 1
- ACIU 2
- Target Price
- SSBK $36.00
- ACIU $12.00
- AVG Volume (30 Days)
- SSBK 24.0K
- ACIU 147.0K
- Earning Date
- SSBK 01-21-2025
- ACIU 03-13-2025
- Dividend Yield
- SSBK 1.04%
- ACIU N/A
- EPS Growth
- SSBK 3.86
- ACIU N/A
- EPS
- SSBK 3.67
- ACIU N/A
- Revenue
- SSBK $94,140,000.00
- ACIU $48,505,404.00
- Revenue This Year
- SSBK N/A
- ACIU $86.72
- Revenue Next Year
- SSBK $11.75
- ACIU $118.28
- P/E Ratio
- SSBK $9.29
- ACIU N/A
- Revenue Growth
- SSBK 13.56
- ACIU 4097200.00
- 52 Week Low
- SSBK $22.13
- ACIU $2.25
- 52 Week High
- SSBK $39.16
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- SSBK 55.59
- ACIU 39.10
- Support Level
- SSBK $33.05
- ACIU $2.56
- Resistance Level
- SSBK $35.28
- ACIU $2.83
- Average True Range (ATR)
- SSBK 1.08
- ACIU 0.16
- MACD
- SSBK 0.28
- ACIU -0.00
- Stochastic Oscillator
- SSBK 85.24
- ACIU 16.85
About SSBK Southern States Bancshares Inc.
Southern States Bancshares Inc is a full-service community banking institution, that offers an array of deposit, loan, and other banking-related products and services to businesses and individuals in communities. It has three portfolio segments Real estate, Commercial and industrial, Consumer and other.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.